content: <?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
    <headerData>
      <submissionType>144</submissionType>
      <filerInfo>
        <filer>
          <filerCredentials>
            <!-- Field: Pseudo-Tag; ID: Name; Data: NOVO NORDISK A S -->
            <cik>0000353278</cik>
            <ccc>XXXXXXXX</ccc>
          </filerCredentials>
        </filer>
        <liveTestFlag>LIVE</liveTestFlag>
  
  
  
      </filerInfo>
    </headerData>
    <formData>
      <issuerInfo>
        <issuerCik>0001598599</issuerCik>
        <issuerName>Innate Pharma SA</issuerName>
        <secFileNumber>001-39084</secFileNumber>
        <issuerAddress>
          <com:street1>117, Avenue de Luminy - BP 30191</com:street1>
          <com:city>Marseille</com:city>
          <com:stateOrCountry>I0</com:stateOrCountry>
          <com:zipCode>13009</com:zipCode>
        </issuerAddress>
        <issuerContactPhone>33-0-4-30-30-30-30</issuerContactPhone>
        <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Novo Nordisk A/S</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
        <relationshipsToIssuer>
          <relationshipToIssuer>10% Stockholder</relationshipToIssuer>
        </relationshipsToIssuer>
      </issuerInfo>
      <securitiesInformation>
        <securitiesClassTitle>Ordinary Shares, nominal value (euro)0.05 per share</securitiesClassTitle>
        <brokerOrMarketmakerDetails>
          <name>Portzamparc</name>
          <address>
            <com:street1>1 boulevard Haussmann</com:street1>
            <com:city>Paris</com:city>
            <com:stateOrCountry>I0</com:stateOrCountry>
            <com:zipCode>75009</com:zipCode>
          </address>
        </brokerOrMarketmakerDetails>
        <noOfUnitsSold>921897</noOfUnitsSold>
        <aggregateMarketValue>1972859.00</aggregateMarketValue>
        <noOfUnitsOutstanding>92189798</noOfUnitsOutstanding>
        <approxSaleDate>05/30/2025</approxSaleDate>
        <securitiesExchangeName>Euronext Nasdaq</securitiesExchangeName>
      </securitiesInformation>
      <securitiesToBeSold>
        <securitiesClassTitle>Ordinary Shares, (euro)0.05 nominal value per share</securitiesClassTitle>
        <acquiredDate>06/11/2006</acquiredDate>
        <natureOfAcquisitionTransaction>Acquisition</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>4691651</amountOfSecuritiesAcquired>
        <paymentDate>06/11/2006</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <securitiesToBeSold>
        <securitiesClassTitle>Ordinary Shares, (euro)0.05 nominal value per share</securitiesClassTitle>
        <acquiredDate>12/18/2009</acquiredDate>
        <natureOfAcquisitionTransaction>Acquisition</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>881057</amountOfSecuritiesAcquired>
        <paymentDate>12/18/2009</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <securitiesToBeSold>
        <securitiesClassTitle>Ordinary Shares, (euro)0.05 nominal value per share</securitiesClassTitle>
        <acquiredDate>06/23/2014</acquiredDate>
        <natureOfAcquisitionTransaction>Acquisition</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>250000</amountOfSecuritiesAcquired>
        <paymentDate>06/23/2014</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <securitiesToBeSold>
        <securitiesClassTitle>Ordinary Shares, (euro)0.05 nominal value per share</securitiesClassTitle>
        <acquiredDate>12/28/2016</acquiredDate>
        <natureOfAcquisitionTransaction>Acquisition</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>142000</amountOfSecuritiesAcquired>
        <paymentDate>12/28/2016</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <securitiesToBeSold>
        <securitiesClassTitle>Ordinary Shares, (euro)0.05 nominal value per share</securitiesClassTitle>
        <acquiredDate>01/18/2017</acquiredDate>
        <natureOfAcquisitionTransaction>Licensing Deal</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>600000</amountOfSecuritiesAcquired>
        <paymentDate>01/18/2017</paymentDate>
        <natureOfPayment>Novo Nordisk A/S received the ordinary shares in connection with a licensing deal.</natureOfPayment>
      </securitiesToBeSold>
      <securitiesToBeSold>
        <securitiesClassTitle>Ordinary Shares, (euro)0.05 nominal value per share</securitiesClassTitle>
        <acquiredDate>10/17/2019</acquiredDate>
        <natureOfAcquisitionTransaction>Acquisition</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>909000</amountOfSecuritiesAcquired>
        <paymentDate>10/17/2019</paymentDate>
        <natureOfPayment>Cash</natureOfPayment>
      </securitiesToBeSold>
      <securitiesToBeSold>
        <securitiesClassTitle>Ordinary Shares, (euro)0.05 nominal value per share</securitiesClassTitle>
        <acquiredDate>12/08/2020</acquiredDate>
        <natureOfAcquisitionTransaction>Licensing Deal</natureOfAcquisitionTransaction>
        <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
        <isGiftTransaction>N</isGiftTransaction>
        <amountOfSecuritiesAcquired>3343748</amountOfSecuritiesAcquired>
        <paymentDate>12/08/2020</paymentDate>
        <natureOfPayment>Novo Nordisk A/S received the ordinary shares in connection with a licensing deal.</natureOfPayment>
      </securitiesToBeSold>
      <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
      <remarks>The sales are expected to occur on the Euronext Paris.</remarks>
      <noticeSignature>
        <noticeDate>05/30/2025</noticeDate>
        <signature>/s/ Martin Huseboe</signature>
      </noticeSignature>
    </formData>
  </edgarSubmission>
metadata_documents: [{"type": "144", "sequence": "1", "filename": "primary_doc.xml", "secsgml_size_bytes": 6507}]
text: 144
  0000353278
  XXXXXXXX
  LIVE
  0001598599
  Innate Pharma SA
  001-39084
  117, Avenue de Luminy - BP 30191
  Marseille
  I0
  13009
  33-0-4-30-30-30-30
  Novo Nordisk A/S
  10% Stockholder
  Ordinary Shares, nominal value (euro)0.05 per share
  Portzamparc
  1 boulevard Haussmann
  Paris
  I0
  75009
  921897
  1972859.00
  92189798
  05/30/2025
  Euronext Nasdaq
  Ordinary Shares, (euro)0.05 nominal value per share
  06/11/2006
  Acquisition
  Issuer
  N
  4691651
  06/11/2006
  Cash
  Ordinary Shares, (euro)0.05 nominal value per share
  12/18/2009
  Acquisition
  Issuer
  N
  881057
  12/18/2009
  Cash
  Ordinary Shares, (euro)0.05 nominal value per share
  06/23/2014
  Acquisition
  Issuer
  N
  250000
  06/23/2014
  Cash
  Ordinary Shares, (euro)0.05 nominal value per share
  12/28/2016
  Acquisition
  Issuer
  N
  142000
  12/28/2016
  Cash
  Ordinary Shares, (euro)0.05 nominal value per share
  01/18/2017
  Licensing Deal
  Issuer
  N
  600000
  01/18/2017
  Novo Nordisk A/S received the ordinary shares in connection with a licensing deal.
  Ordinary Shares, (euro)0.05 nominal value per share
  10/17/2019
  Acquisition
  Issuer
  N
  909000
  10/17/2019
  Cash
  Ordinary Shares, (euro)0.05 nominal value per share
  12/08/2020
  Licensing Deal
  Issuer
  N
  3343748
  12/08/2020
  Novo Nordisk A/S received the ordinary shares in connection with a licensing deal.
  Y
  The sales are expected to occur on the Euronext Paris.
  05/30/2025
  /s/ Martin Huseboe